Study Notes · Pediatrics Part One

Why the Same mg/kg Dose Can Hit a Neonate Harder Than a Toddler

Weight-based dosing looks like simple arithmetic — scale the dose to the kilograms and the drug behaves the same way. It doesn't. A neonate and a four-year-old at an identical mg/kg dose are not receiving an equivalent clinical exposure, and the reasons are pharmacokinetic, not mathematical.

Two Organs That Aren't Finished Developing

Glomerular filtration rate doesn't reach adult levels until roughly one to two years of age, which means renal drug clearance in a neonate or young infant is genuinely slower than the same weight-based dose would suggest. Hepatic clearance tells a parallel story: the CYP enzyme systems responsible for metabolising a large share of commonly used drugs, particularly CYP3A4 and CYP1A2, are incompletely expressed at birth and mature gradually through infancy.

For drugs with a narrow therapeutic index — morphine, midazolam, and lidocaine are the standouts — this immaturity translates directly into prolonged half-lives. A dosing interval that's appropriate for a toddler can mean cumulative, compounding exposure in a neonate receiving the same drug on the same schedule.

Where the Drug Actually Goes

Total body water as a proportion of body weight is highest in neonates, around 75%, and steadily decreases with age. That matters specifically for hydrophilic drugs, which will distribute into a proportionally larger volume in a neonate or young infant than in an older child — diluting the drug more, but also meaning the pharmacokinetics of loading and clearance don't scale linearly with weight alone.

Protein binding compounds the issue in the opposite direction. Serum albumin is lower in neonates, so highly protein-bound drugs — fentanyl and diazepam are common examples — have a higher proportion of free, pharmacologically active drug circulating at an equivalent total dose. The therapeutic and adverse effects of the same nominal dose are both amplified as a direct consequence.

The synthesis. A larger volume of distribution tends to dilute a drug's initial concentration, while lower protein binding tends to concentrate its free, active fraction. These two effects don't cancel out predictably — they interact differently for every drug depending on its water solubility and protein affinity, which is exactly why generic weight-based scaling isn't a substitute for age-appropriate, drug-specific dosing guidance.

Why the Broselow Tape Isn't Just a Sizing Chart

Length-based tools like the Broselow tape exist precisely because caregiver-estimated weight is unreliable under pressure, but their real clinical value goes beyond convenience. By pairing weight estimation directly with pre-calculated equipment sizes and drug doses, they reduce the cognitive load of doing pharmacokinetic reasoning in real time on scene — reasoning that, as the physiology above shows, is genuinely complex even before you account for an unwell, poorly perfused child whose absorption and distribution may already be altered by their acute presentation.

The tape has real limitations. It estimates weight from length and will systematically underestimate weight in obese children, where actual body weight can overestimate the appropriate dose for lipophilic drugs, sedatives, and opioids — ideal or lean body weight is the more appropriate basis in that population, not measured weight.

The Clinical Takeaway

Treating a neonate as a scaled-down toddler, and a toddler as a scaled-down adult, is the error underneath a meaningful share of pediatric medication harm. Renal and hepatic immaturity slow clearance in the smallest patients. Volume of distribution and protein binding shift how much free drug is active at any given dose. None of this shows up on a Broselow tape as a warning label — it shows up as a neonate who reacts to a textbook-correct mg/kg dose more strongly, and for longer, than the toddler in the next bay.